Subclavian Steal Syndrome Medication

Updated: Apr 09, 2019
  • Author: Iman Bayat, MBBS, MRCS, FRACS; Chief Editor: Vincent Lopez Rowe, MD  more...
  • Print
Medication

Medication Summary

The goals of pharmacotherapy are to reduce morbidity and prevent complications.

Next:

Antiplatelet Agents, Cardiovascular

Class Summary

Antiplatelet agents inhibit platelet aggregation and reduce ischemic events. Patients should be treated with lifelong antiplatelet therapy to reduce the risk of associated myocardial infarction, stroke, and other vascular causes of death, if the cause of subclavian steal syndrome is determined to be atherosclerotic stenosis or occlusion of the proximal subclavian artery.

Aspirin (Bayer Aspirin, Ascriptin Maximum Strength, Ecotrin, Bufferin)

Aspirin inhibits prostaglandin synthesis, which prevents the formation of platelet-aggregating thromboxane A2.

Clopidogrel (Plavix)

Clopidogrel selectively inhibits adenosine diphosphate (ADP) binding to platelet receptors and subsequent ADP-mediated activation of the glycoprotein (GP) IIb/IIIa complex, thereby inhibiting platelet aggregation.

Ticlopidine

Ticlopidine hydrochloride interferes with platelet membrane function by inhibiting adenosine diphosphate (ADP)–induced platelet-fibrinogen binding and subsequent platelet-platelet interaction. It is used as a second-line antiplatelet therapy for patients who are intolerant of aspirin therapy or in whom such therapy fails.

Previous